Novel Therapeutic Strategies With Alemtuzumab for Chronic Lymphocytic Leukemia

Seminars in Oncology

Volumn 33, Issue SUPPL. 5, 2006, Pages 15-22

  Rai, Kanti R ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; COTRIMOXAZOLE; IMMUNOMODULATING AGENT; VALACICLOVIR;

ARTICLE; BONE MARROW CELL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TOLERABILITY; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; INFLUENZA; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 33646555741     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.025     Document Type: Article

References (53)

1. Jemal A., Murray T., Ward E., et al. Cancer Statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Rai K.R., and Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1797-1799
3. French Cooperative Group on Chronic Lymphocytic Leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. Leuk Lymphoma 13 (1994) 449-456
4. Jaksic B., Brugiatelli M., Krc I., et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 79 (1997) 2107-2114
5. Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98 (2001) 2319-2325
6. Keating M.J., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92 (1998) 1165-1171
7. Johnson S., Smith A.G., Loffler H., et al., The French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347 (1996) 1432-1438
8. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Eng J Med 343 (2000) 1750-1757
9. Genini D., Budihardjo I., Plunkett W., et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 275 (2000) 29-34
10. Genini D., Adachi S., Chao Q., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96 (2000) 3537-3543
11. Shieh S.Y., Ikeda M., Taya Y., et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 (1997) 325-334
12. Thornton P.D., Gruszka-Westwood A.M., Hamoudi R.A., et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 5 (2004) 47-54
13. Fenaux P., Preudhomme C., Lai J.L., et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia. A report on 39 cases with cytogenetic analysis. Leukemia 6 (1992) 246-250
14. Callet-Bauchu E., Salles G., Gazzo S., et al. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders. Frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia 13 (1999) 460-468
15. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3278-3281
16. Keating M.J., O'Brien S., Kontoyiannis D., et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43 (2002) 1755-1762
17. Österborg A., Dyer M.J., Bunjes D., et al., European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15 (1997) 1567-1574
18. Rawstron A., Davies C., Evans P., et al. CAMPATH-1H therapy for patients with refractory chronic lymphocytic leukaemia. Blood 90 (1997) 2356 (abstr)
19. Stilgenbauer S., Scherer K., Krobler A., et al. Campath-1H in refractory CLL-Complete remission despite p53 gene mutation. Blood 98 (2001) 3211 (abstr)
20. McCune S.L., Gockerman J.P., Moore J.O., et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 43 (2002) 1007-1011
21. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20 (2002) 3891-3897
22. Ferrajoli A., O'Brien S.M., Cortes J.E., et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98 (2003) 773-778
23. Rai K.R., Keating M.J., Coutre S., et al. Patients with refractory B-CLL and T-PLL treated with alemtuzumab (CamPath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial. Blood 100 (2002) 3165 (abstr)
24. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine. Results of a large international study. Blood 99 (2002) 3554-3561
25. Stilgenbauer S., Winkler D., Krober A., et al. Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL. Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG). Blood 104 (2004) 478 (abstr)
26. Hale G., Rebello P., Brettman L., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104 (2004) 948-955
27. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
28. Hillmen P., Skotnicki A., Robak T., et al. Preliminary safety and efficacy report of randomized trial of alemtuzumab vs. chlorambucil as front-line in 297 patients with progressive B-cell chronic lymphocytic leukemia. Blood 104 (2004) 2505
29. Rawstron A.C., Kennedy B., Evans P.A., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98 (2001) 29-35
30. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (2005) 2971-2979
31. Rai K.R., Byrd J., Peterson B., et al. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease. Cancer and Leukemia Group B (CALGB) study 19901. Blood 100 (2002) 772 (abstr)
32. Rai K.R., Byrd J., Peterson B., et al. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL). CALGB Study 19901. Blood 102 (2003) 2506 (abstr)
33. O'Brien S., Gribben J.G., Thomas D.A., et al. Alemtuzumab for minimal residual disease in CLL. Blood 102 (2003) 371 (abstr)
34. O'Brien S.M., Kantarjian H.M., Thomas D.A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 (2003) 2657-2663
35. Montillo M., Tedeschi A., Rossi V., et al. Consolidation with alemtuzumab after a response to fludarabine in patients with CLL. Confirmation of the efficacy to purge residual disease. Leuk Lymphoma 46 suppl 1 (2005) S93 (abstr)
36. Wendtner C.M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (2004) 1093-1101
37. Ritgen M., Schweighofer C., Fingerle-Rowson G., et al. Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions-Update on randomized phase III trial of the German CLL Study Group (GCLLSG). Blood 104 (2004) 2506 (abstr)
38. Elter T., Borchmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Results of a Phase II trial. J Clin Oncol 23 (2005) 7024-7031
39. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med 343 (2000) 1910-1916
40. Dohner H., Fishcer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic-B-cell leukemias. Blood 85 (1995) 1580-1589
41. El Rouby S., Thomas A., Costin D., et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82 (1993) 3452-3459
42. Sturm I., Bosanquet A.G., Hermann S., et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Diff 10 (2003) 477-484
43. Byrd J.C., Smith L., Hackbarth M.L., et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 63 (2003) 36-38
44. Byrd J.C., Gribben J.G., Peterson B., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL). Preliminary justification for risk-adapted therapy. Blood 104 (2004) 476 (abstr)
45. Grever M.R., Lucas D.M., Dewald G.W., et al. Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely implicated by high risk genetic features. results from ECOG 2997. Blood 104 (2004) 3487 (abstr)
46. Lucas D.M., Dewald G.W., Neuberg D.S., et al. Clinical, laboratory, and treatment outcome characteristics of chronic lymphocytic leukemia (CLL) patients with p53mutations or del(17p) enrolled in a prospective phase III clinical trial. Short progression free survival, irrespective of fludarabine-based treatment used. Blood 104 (2004) 949 (abstr)
47. Catovsky D., Richards S., Matutes E., et al. Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial. Blood 104 (2004) 13 (abstr)
48. Stilgenbauer S., Winkler D., Krober A., et al. Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL. Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG). Blood 104 (2004) 478 (abstr)
49. Cortelezzi A., Pasquini M.C., Sarina B., et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 90 (2005) 410-412
50. Osuji N., Giudice I.D., Matutes E., et al. Alemtuzumab for chronic lymphocytic leukemia with and without p53 deletions. Blood 104 (2004) 2510 (abstr)
51. Kimby E., Wallblom A., Merup M., et al. Alemtuzumab (Campath-1H) S.C. is effective in patients with B-CLL with adverse chromosomal aberrations. Abstracts of the 10th Congress of the European Hematology Association (2005) 1258 (abstr)
52. Rai K.R., Janson D., Driscoll N., et al. Varying modes of maintenance therapy with Campath-1H in chronic lymphocytic leukemia (CLL). Blood 103 (2002) 1099 (abstr)
53. Thieblemont C., Bouafia F., Hornez E., et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic leukemia (B-CLL/SLL). Leuk Lymphoma 45 (2004) 711-714